- Home
- BRNS vs AKTX Comparison
BRNS vs AKTX Comparison
Compare BRNS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- AKTX
- Stock Information
- Founded
- BRNS 2016
- AKTX N/A
- Country
- BRNS United Kingdom
- AKTX United States
- Employees
- BRNS N/A
- AKTX N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- AKTX Health Care
- Exchange
- BRNS Nasdaq
- AKTX Nasdaq
- Market Cap
- BRNS 40.0M
- AKTX 41.8M
- IPO Year
- BRNS 2021
- AKTX N/A
- Fundamental
- Price
- BRNS $0.92
- AKTX $1.17
- Analyst Decision
- BRNS Strong Buy
- AKTX
- Analyst Count
- BRNS 1
- AKTX 0
- Target Price
- BRNS $3.00
- AKTX N/A
- AVG Volume (30 Days)
- BRNS 18.8K
- AKTX 27.5K
- Earning Date
- BRNS 08-07-2025
- AKTX 08-18-2025
- Dividend Yield
- BRNS N/A
- AKTX N/A
- EPS Growth
- BRNS N/A
- AKTX N/A
- EPS
- BRNS N/A
- AKTX N/A
- Revenue
- BRNS $14,969,000.00
- AKTX N/A
- Revenue This Year
- BRNS N/A
- AKTX N/A
- Revenue Next Year
- BRNS N/A
- AKTX N/A
- P/E Ratio
- BRNS N/A
- AKTX N/A
- Revenue Growth
- BRNS 4381.74
- AKTX N/A
- 52 Week Low
- BRNS $0.64
- AKTX $0.85
- 52 Week High
- BRNS $1.58
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- BRNS 50.69
- AKTX 44.68
- Support Level
- BRNS $0.83
- AKTX $1.09
- Resistance Level
- BRNS $0.95
- AKTX $1.22
- Average True Range (ATR)
- BRNS 0.05
- AKTX 0.08
- MACD
- BRNS -0.01
- AKTX -0.00
- Stochastic Oscillator
- BRNS 45.35
- AKTX 40.00
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.